Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J., Williams C., STAPLIN N., Judge P., Mayne K., Agrawal N., ARIMOTO R., Green J., Cherney D., Tuttle K., LEAL J., CLARKE P., EMBERSON J., PREISS D., Wanner C., LANDRAY M., Baigent C., HAYNES R., HERRINGTON W., MIHAYLOVA B.

Type

Journal

EClinicalMedicine

Publisher

Elsevier

Publication Date

19/06/2025

Permalink